Piper Sandler Reiterates Overweight on TransMedics Group, Raises Price Target to $125

Benzinga · 4d ago
Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and raises the price target from $105 to $125.